Journal Club VL

Improvement in rPFS with Abiraterone Plus Olaparib Over Abiraterone Plus Placebo in First-Line mCRPC Irrespective of HRR Mutation Status, The PROpel Trial Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club, Zachary Klaassen reviews the PROpel study and the New England Journal of Medicine Evidence publication entitled Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer . PROpel is a randomized phase III trial of abiraterone plus olaparib versus abiraterone plus placebo as first-line therapy for patients with metastatic castration-resistant prosta...

Sustained Benefit to Metastasis-Directed Therapy Versus Observation: A Pooled Analysis of the STOMP and ORIOLE Trials Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club, Zachary Klaassen reviews the Journal of clinical oncology publication entitled Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials . The authors use two independent phase II trials, each of which enrolled men with oligometastatic prostate cancer...

Nivolumab/Ipilimumab (Nivo/Ipi) with or Without CBM588 in Metastatic Renal Cell Carcinoma Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club, Zachary Klaassen reviews the Nature Medicine publication entitled Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nivo and ipi first demonstrated to have a benefit in this setting in the CheckMate 214 trial. However, the vast majority of patients still don't have a response, and...

Atezolizumab as Adjuvant Therapy After Resection for Patients with Renal Cell Carcinoma with Increased Risk of Recurrence: IMmotion010 Trial, Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review the Lancet publication Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Approximately 80% of patients, present initially with local regional disease. However, despite the i...

10-year Results DART 01-05, High-dose Radiotherapy and Risk-adapted Androgen Deprivation in Localized Prostate Cancer Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen review The Lancet Oncology publication High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05) looking at its 10-year results. Radiotherapy is a standard treatment option in patients with localized prostate cancer. With conventional dosing of radiotherapy, the addition of androgen...

VIABLE Phase 3 Trial: Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With mCPRC, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club Christopher Wallis and Zach Klaassen highlight a JAMA oncology publication entitled Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial. VIABLE sought to evaluate the efficacy and safety of DCVAC/PCa plus...

Electronic Symptom Monitoring During Cancer Treatment for Improved Quality of Life, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club Christopher Wallis and Zach Klaassen highlight a JAMA publication entitled the Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer. Symptom monitoring allows for the detection and treatment of symptoms, which may improve outcomes for cancer patients. The use of an electronic system to facilitate patient-reported o...

223Ra Use Before 177Lu-PSMA for Patients with Bone-predominant mCRPC, The RAdium LUtetium (RALU) Study, Journal Club - Zachary Klaassen

Details
In this UroToday Journal Club Chris Wallis and Zach Klaassen highlight a Journal of Nuclear Medicine publication entitled Safety and Survival Outcomes of Lutetium-177-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with prior Radium-223 treatment: The RALU Study . The RAdium LUtetium (RALU) study evaluated the feasibility of sequential al...

Recovery and Morbidity After Robot-Assisted Radical Cystectomy With Intracorporeal Reconstruction vs Open Radical Cystectomy, the iROC Trial, Journal Club – Christopher Wallis & Zachary Klaassen

Details
Christopher Wallis and Zachary Klaassen discuss the results of the iROC trial, a JAMA publication titled the Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer: A Randomized Clinical Trial . The iROC trial aimed to compare totally intracorporeal robotic assisted radical cy...

Reducing Treatment Burden For Patients with Localized GG 2 or 3 Intermediate-Risk Prostate Cancer with MRI-Guided Focused Ultrasound Focal Therapy, Journal Club - Christopher Wallis & Zachary Klaassen

Details
In this UroToday Journal Club video presentation Christopher Wallis and Zachary Klaassen highlight a The Lancet Oncology publication titled MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. A study which aimed to investigate whether MRI-guided focused ultrasound focal therapy can safely reduce treatment burden for patien...